{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T23:14:51Z","timestamp":1767395691634},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13256-016-0875-x","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T02:02:17Z","timestamp":1463191337000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Single-agent MOR208 salvage and maintenance therapy in a patient with refractory\/relapsing diffuse large B-cell lymphoma: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Wojciech","family":"Jurczak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata Hanna","family":"Bryk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Ga\u0142\u0105zka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Trofimiuk\u2013M\u00fcldner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Wyrobek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sawiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander B.","family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,14]]},"reference":[{"issue":"5","key":"875_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/PPO.0b013e31826aee97","volume":"18","author":"MP Menon","year":"2012","unstructured":"Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012;18(5):411\u201320. doi: 10.1097\/PPO.0b013e31826aee97 .","journal-title":"Cancer J"},{"issue":"12","key":"875_CR2","first-page":"1074","volume":"28","author":"J Boyle","year":"2014","unstructured":"Boyle J, Beaven AW, Diehl LF, Prosnitz LR, Kelsey CR. Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. Oncology (Williston Park). 2014;28(12):1074\u201381. 84.","journal-title":"Oncology (Williston Park)."},{"issue":"Suppl 7","key":"875_CR3","doi-asserted-by":"crossref","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","volume":"23","author":"H Tilly","year":"2012","unstructured":"Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii78\u201382. doi: 10.1093\/annonc\/mds273 .","journal-title":"Ann Oncol."},{"issue":"27","key":"875_CR4","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390. doi: 10.1200\/JCO.2010.28.1618 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"875_CR5","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","volume":"115","author":"FT Awan","year":"2010","unstructured":"Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115(6):1204\u201313. doi: 10.1182\/blood-2009-06-229039 .","journal-title":"Blood"},{"issue":"19","key":"875_CR6","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049\u201357. doi: 10.1158\/0008-5472.CAN-08-2268 .","journal-title":"Cancer Res"},{"issue":"24","key":"875_CR7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","volume":"124","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124(24):3553\u201360. doi: 10.1182\/blood-2014-08-593269 .","journal-title":"Blood"},{"issue":"4","key":"875_CR8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.11-4-384","volume":"11","author":"JS Abramson","year":"2006","unstructured":"Abramson JS. T-cell\/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006;11(4):384\u201392. doi: 10.1634\/theoncologist.11-4-384 .","journal-title":"Oncologist"},{"key":"875_CR9","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987\u201394. doi:10.1056\/NEJM199309303291402","DOI":"10.1056\/NEJM199309303291402"},{"issue":"14","key":"875_CR10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136. doi: 10.1056\/NEJM199304083281404 .","journal-title":"N Engl J Med"},{"issue":"4","key":"875_CR11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. doi: 10.1056\/NEJMoa011795 .","journal-title":"N Engl J Med"},{"issue":"2","key":"875_CR12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","volume":"111","author":"E Vellenga","year":"2008","unstructured":"Vellenga E, van Putten WL, van \u2018t Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111(2):537\u201343. doi: 10.1182\/blood-2007-08-108415 .","journal-title":"Blood"},{"issue":"10","key":"875_CR13","first-page":"3562","volume":"92","author":"J Blay","year":"1998","unstructured":"Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group Blood. 1998;92(10):3562\u20138.","journal-title":"Parma Group. Blood."},{"issue":"31","key":"875_CR14","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079\u201387. doi: 10.1200\/JCO.2011.35.4423 .","journal-title":"J Clin Oncol"},{"issue":"5","key":"875_CR15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","volume":"4","author":"O Hammer","year":"2012","unstructured":"Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs. 2012;4(5):571\u20137. doi: 10.4161\/mabs.21338 .","journal-title":"MAbs"},{"issue":"suppl","key":"875_CR16","doi-asserted-by":"crossref","first-page":"abstr 8500","DOI":"10.1200\/jco.2015.33.15_suppl.8500","volume":"33","author":"W Jurczak","year":"2015","unstructured":"Jurczak W, Zinzani P, Goy A, Provencio M, Nagy Z, Robak T, et al. Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma (NHL). J Clin Oncol. 2015;33(suppl):abstr 8500.","journal-title":"J Clin Oncol."},{"issue":"12","key":"875_CR17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356. doi: 10.1182\/blood-2007-06-093906 .","journal-title":"Blood"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-0875-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T17:20:40Z","timestamp":1567876840000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-0875-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-0875-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,14]]},"article-number":"123"}}